This page shows the details of why an item matched the keywords from your search.
| Property | Value |
|
overview
|
Samuel Lab Research Interest Areas
1. Enhancing the efficacy of anti-cancer therapy. The efficacy of cancer therapy is severely compromised due to serious side effects and resistance. Our laboratory is interested in improving the outcomes of cancer therapy through:
a. Understanding of the molecular responses in cells exposed to clinically used targeted or broad-acting therapeutic agents. We characterize the activation of critical signaling mechanisms when neoplastic epithelial or stromal cells are exposed to therapeutic drugs.
b. Designing rational combination strategies that will improve the therapeutic index of clinically used drugs. We test natural compounds and novel agents for their enhancing activities when combined with known anti-neoplastic agents. The overarching goal of our research interest in this area is to rationalize the use of combination therapy in cancer management. We employ molecular and cell biology techniques as well as in vitro cell line and in vivo preclinical models to address these questions.
c. Strategies using nanomaterial- or biomimetic vehicles for drug delivery. In collaboration with Material Sciences Engineering department faculty, we formulate and test bio-derived nanomaterials for delivery of drugs that would otherwise be unstable for example in the upper digestive tract or would not reach distal organs such as the large bowel.
2. Collaborative: Development of molecular tools and novel methods for the detection of pathogens. Projects in this area are focused on developing rapid and sensitive strategies to detect pathogens that cause major foodborne diseases. Specifically, we work on establishing molecular and nanotechnology-based tools to reduce the time length for pathogen identification after an outbreak or overt disease.
|
One or more keywords matched the following items that are connected to
Samuel, Temesgen
| Item Type | Name |
|
Grant
|
Quercetin as an enhancer of the efficacy of 5-FU in mouse models of colon cancer
|
|
Academic Article
|
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
|
|
Academic Article
|
Variable NF-?B pathway responses in colon cancer cells treated with chemotherapeutic drugs.
|
|
Concept
|
Alkylating Agents
|
|
Concept
|
Ampicillin
|
|
Concept
|
Anti-Bacterial Agents
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Concept
|
Antioxidants
|
|
Concept
|
Camptothecin
|
|
Concept
|
Chloramphenicol
|
|
Concept
|
Cysteine Endopeptidases
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
DNA, Bacterial
|
|
Concept
|
DNA, Neoplasm
|
|
Concept
|
Ecdysone
|
|
Concept
|
Etoposide
|
|
Concept
|
Exonucleases
|
|
Concept
|
Exoribonucleases
|
|
Concept
|
Flavonoids
|
|
Concept
|
Fluorouracil
|
|
Concept
|
Fucosyltransferases
|
|
Concept
|
Glutathione Transferase
|
|
Concept
|
Indenes
|
|
Concept
|
Indoles
|
|
Concept
|
Membrane Proteins
|
|
Concept
|
Methylnitrosourea
|
|
Concept
|
Microfilament Proteins
|
|
Concept
|
Microtubule-Associated Proteins
|
|
Concept
|
Multienzyme Complexes
|
|
Concept
|
Nalidixic Acid
|
|
Concept
|
Neoplasm Proteins
|
|
Concept
|
Nerve Tissue Proteins
|
|
Concept
|
Organoplatinum Compounds
|
|
Concept
|
Phenylurea Compounds
|
|
Concept
|
Phleomycins
|
|
Concept
|
Plant Extracts
|
|
Concept
|
Plasmids
|
|
Concept
|
Tissue Plasminogen Activator
|
|
Concept
|
Polyesters
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Proteins
|
|
Concept
|
Quercetin
|
|
Concept
|
Quinazolines
|
|
Concept
|
Receptors, Estrogen
|
|
Concept
|
Receptors, Steroid
|
|
Concept
|
Recombinant Fusion Proteins
|
|
Concept
|
Recombinant Proteins
|
|
Concept
|
Silver
|
|
Concept
|
Stilbenes
|
|
Concept
|
Sulfisoxazole
|
|
Concept
|
Tetracycline
|
|
Concept
|
Transcription Factors
|
|
Concept
|
Tubulin
|
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Viral Proteins
|
|
Concept
|
Nocodazole
|
|
Concept
|
Serpins
|
|
Concept
|
Cysteine Proteinase Inhibitors
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
NF-kappa B
|
|
Concept
|
RNA-Binding Proteins
|
|
Concept
|
Apoptosis
|
|
Concept
|
Paclitaxel
|
|
Concept
|
Lignans
|
|
Concept
|
DNA Primers
|
|
Concept
|
Azithromycin
|
|
Concept
|
Cell Cycle Proteins
|
|
Concept
|
Microsatellite Repeats
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Caspases
|
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
|
Concept
|
Mitochondrial Proteins
|
|
Concept
|
Tumor Suppressor Proteins
|
|
Concept
|
Ubiquitin
|
|
Concept
|
Tumor Suppressor Protein p14ARF
|
|
Concept
|
Zebrafish Proteins
|
|
Concept
|
RNA, Small Interfering
|
|
Concept
|
Ubiquitin-Protein Ligases
|
|
Concept
|
Proteasome Endopeptidase Complex
|
|
Concept
|
Receptors, Tumor Necrosis Factor, Type I
|
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
|
Concept
|
TNF Receptor-Associated Factor 2
|
|
Concept
|
Extracellular Signal-Regulated MAP Kinases
|
|
Concept
|
14-3-3 Proteins
|
|
Concept
|
Receptors, Lysophosphatidic Acid
|
|
Concept
|
Tubulin Modulators
|
|
Concept
|
Plasma Membrane Neurotransmitter Transport Proteins
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p27
|
|
Concept
|
bcl-2 Homologous Antagonist-Killer Protein
|
|
Concept
|
Apoptosis Regulatory Proteins
|
|
Concept
|
bcl-X Protein
|
|
Concept
|
bcl-2-Associated X Protein
|
|
Concept
|
Inhibitor of Apoptosis Proteins
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
X-Linked Inhibitor of Apoptosis Protein
|
|
Concept
|
Smad4 Protein
|
|
Concept
|
Caspase 3
|
|
Concept
|
Receptor-Interacting Protein Serine-Threonine Kinases
|
|
Concept
|
CASP8 and FADD-Like Apoptosis Regulating Protein
|
|
Concept
|
Caspase 9
|
|
Concept
|
Cyclin B1
|